Real-time biotech intelligence for serious traders

Modern biotech data

1,000+ companies. 5,000+ clinical trials. FDA catalysts scored by significance. All the data Wall Street uses — at a fraction of the cost.

Start FreeView Pricing

No credit card required. Free tier available forever.

LLY$905.03-1.89%
NVO$39.32+3.53%
ABBV$210.26+1.84%
MRNA$54.26+2.69%
PFE$27.11-0.76%
AMGN$350.95+0.30%
GILD$140.45+1.02%
VRTX$444.28+1.01%
REGN$668.85-0.44%
BIIB$134.20-2.10%
ALNY$333.39-1.77%
INCY$55.80+0.92%
LLY$905.03-1.89%
NVO$39.32+3.53%
ABBV$210.26+1.84%
MRNA$54.26+2.69%
PFE$27.11-0.76%
AMGN$350.95+0.30%
GILD$140.45+1.02%
VRTX$444.28+1.01%
REGN$668.85-0.44%
BIIB$134.20-2.10%
ALNY$333.39-1.77%
INCY$55.80+0.92%

1,054

Biotech Companies

5,400+

Clinical Trials

2,800+

Drug Programs

18,000+

SEC Filings

Features

Everything you need to trade biotech

Data from ClinicalTrials.gov, SEC EDGAR, and market feeds — normalized and ready for trading decisions.

Company Screener

Filter and sort 1,000+ US-listed biotech companies by market cap, exchange, therapeutic area, and pipeline stage.

Drug Pipeline Tracker

Track every drug from Phase 1 through approval. See indications, mechanisms, and trial timelines at a glance.

Catalyst Calendar

Never miss an FDA decision or data readout. Catalysts scored by significance with confidence levels.

Options Flow

Visualize call vs put volume by expiration. Put/call ratio and sentiment analysis for every biotech stock.

SEC Filings

Monitor 10-K, 10-Q, 8-K filings and Form 4 insider trades. Spot insider buying before the market does.

Insider Activity

Track insider buying and selling with net activity signals. See who's putting their money where their mouth is.

How It Works

Three steps to smarter trades

01

Search

Find biotech companies by name, ticker, therapeutic area, or pipeline stage.

02

Analyze

Dive into drug pipelines, clinical trials, catalysts, and insider activity.

03

Trade

Make informed decisions with catalyst dates, insider signals, and options data.

Pricing

Simple, transparent pricing

Start free, upgrade when you need the full dataset.

Free

Get started with major biotech companies

$0forever
Start Free
  • Large-cap biotech companies
  • Basic pipeline data
  • Catalyst calendar
  • Limited trial data
  • All companies & small-caps
  • Full SEC filings & insider data
  • Options flow analytics
Most Popular

Pro

Full access to all biotech data

$19.99/month
Upgrade to Pro
  • All 1,000+ biotech companies
  • Complete drug pipelines (2,800+)
  • Full catalyst calendar with scoring
  • 5,400+ clinical trials
  • 18,000+ SEC filings & Form 4 tracking
  • Insider activity signals
  • Options flow analytics
  • Priority data updates

FAQ

Frequently asked questions

Biotech stocks can move 50-200% on a single FDA decision or clinical trial result. A Phase 3 success or new drug approval can double a stock overnight. This volatility creates huge opportunities for informed traders who track catalysts.
PDUFA (Prescription Drug User Fee Act) dates are FDA-mandated deadlines for drug approval decisions. The FDA must respond by the PDUFA date, making them the most predictable binary events in biotech. Stocks often move significantly on these dates.
Phase 1 tests safety in a small group. Phase 2 tests efficacy and dosing. Phase 3 is the pivotal trial with thousands of patients — success here often leads to FDA approval. Phase 4 is post-approval monitoring. Each phase advancement is a bullish catalyst.
A catalyst is any upcoming event that could move a stock's price — FDA decisions, clinical trial data readouts, advisory committee meetings, earnings, or conference presentations. Biotick scores each catalyst by significance so you know which ones matter most.
We aggregate from ClinicalTrials.gov (5,400+ trials), SEC EDGAR (18,000+ filings and insider trades), OpenFDA (approval data), and Finnhub (real-time market data). All data is normalized and cross-referenced.
Stock prices update every 15 minutes during market hours. SEC filings sync every 6 hours. Clinical trials and catalysts update daily. Options flow data refreshes daily.
The put/call ratio measures bearish vs bullish options activity. A ratio above 1.0 means more puts (bearish bets) than calls. Below 0.7 is bullish. In biotech, a rising put/call ratio before a catalyst often signals institutional hedging.
You could, but shorting has unlimited loss potential — one surprise FDA approval or buyout can send a stock up 200% overnight and wipe out all your gains in a single trade. That's why biotech shorting is extremely risky. Many experienced traders have been wiped out by a single binary event going against them.
Yes, cancel anytime from your Stripe billing portal. Your access continues until the end of your billing period. No questions asked.